The New York University Cancer Institute (NYUCI) is seeking funding for its 26th year as an NCI-designated cancer center following a significant re-vitalization of cancer research and treatment activities on the NYU Medical Center campuses that was initiated in 1998. With the recruitment of Dr. Steven Burakoff in 2000 the NYUCI has undergone major expansion. Growth in facilities, faculty recruitment, research productivity, and clinical care has exceeded the benchmarks outlined in strategic plan articulated in the 2002 renewal. During the last funding period, twenty-four faculty in basic, translational and clinical research have been recruited to the NYUCI. Facilities to house research and treatment programs have expanded 400% with the opening the new NYU Clinical Cancer Center and the NYUCI Research Laboratories located within the new Smilow Research Center. Extramural funding has doubled to $64,087,423 (total) in peer reviewed funding and a overall research base of $75,898,561. Funding from the NCI has also doubled and now totals $19,750,445. The Cancer Center Support Grant (CCSG) builds on many unique institutional strengths of this metropolitan hospital center with a highly diverse faculty, staff and patient population. In the current application seven scientific programs are presented for consideration: Cancer Immunology and Immunotherapy, Growth Control, Cancer Stem Cells, Molecular and Environmental Carcinogenesis, Melanoma, Breast Cancer and Genitourinary Cancer. Ten shared resources are supported by the CCSG and two new cores, Vaccine and Cancer Genomics, are presented in the application. The Clinical Trials Office has supported the growth of NYU investigator-initiated studies which now account for 68.7% of all therapeutic accruals. Overall accruals have increased steadily over the past three years from 9.25% in 2004 to 13.3% (projected) in 2006. The NYUCI has fostered an environment that promotes research collaborations and multidisciplinary patient care with 24% of all publications being intra- or interprogrammatic (12% each). The CCSG application continues to be actively supported by the President of NYU, the Dean and CEO of NYU Medical Center, and Hospital and Community leadership who pledge additional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-32
Application #
8232102
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1996-12-01
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
32
Fiscal Year
2012
Total Cost
$2,512,026
Indirect Cost
$1,030,005
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Burgess, Hannah M; Pourchet, Aldo; Hajdu, Cristina H et al. (2018) Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus. Mol Ther Oncolytics 8:71-81
Wong, Serre-Yu; Coffre, Maryaline; Ramanan, Deepshika et al. (2018) B Cell Defects Observed in Nod2 Knockout Mice Are a Consequence of a Dock2 Mutation Frequently Found in Inbred Strains. J Immunol 201:1442-1451
Handler, Jesse; Cullis, Jane; Avanzi, Antonina et al. (2018) Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-? exposure. Oncogene 37:4334-4342
Diamond, Julie M; Vanpouille-Box, Claire; Spada, Sheila et al. (2018) Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res 6:910-920
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001
Khodadadi-Jamayran, Alireza; Akgol-Oksuz, Betul; Afanasyeva, Yelena et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9:12868-12878
Wadghiri, Youssef Z; Hoang, Dung Minh; Leporati, Anita et al. (2018) High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. Sci Rep 8:7687
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247

Showing the most recent 10 out of 1170 publications